-
Mashup Score: 0Source: academic.oup.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
New data coming from Israel shows the Pfizer-BioNTech COVID-19 vaccine did offer some protection initially, but waning immunity occurs rapidly.
Source: Contagion LiveCategories: Infectious Disease, Latest HeadlinesTweet-
“Rates of confirmed SARS-CoV-2 infection and severe #COVID19 were lower after a fourth dose of #BNT162b2 #vaccine than after only three doses.” #secondbooster https://t.co/vK3DKk7T8J
-
-
Mashup Score: 2
Advanced age is a main risk factor for severe COVID-19. However, low vaccination efficacy and accelerated waning immunity have been reported in this age group. To elucidate age-related differences in immunogenicity, we analyzed human cellular, serological, and salivary SARS-CoV-2 spike glycoprotein-
Source: The Journal of ImmunologyCategories: Allergy-Immunology, Latest HeadlinesTweet-
#CuttingEdge from @AndreasJThiel @berlinnovation @ChariteBerlin | Higher #BNT162b2 #COVID #vaccine efficiency in elderly w/preexisting crossreactive #CD4 #Tcells but less durable saliva #IgA versus #convalescents | #ReadTheJI #immunology https://t.co/gBhGzM3jsh https://t.co/aHaTAruHLS
-
-
Mashup Score: 19
This Medical News feature discusses concerns about giving children the BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine despite federal recommendations.
Source: jamanetwork.comCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
Despite @CDCgov and @US_FDA approval of #COVID19 vaccination for children ≥5 years, many parents remain wary. #NEJM research suggests that #BNT162b2 poses no serious adverse effects and is 90.7% effective at preventing COVID-19 in 5- to 11-year-olds. https://t.co/LFpeW1y8Pu
-
-
Mashup Score: 5
This Medical News feature discusses concerns about giving children the BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine despite federal recommendations.
Source: jamanetwork.comCategories: Critical Care, Latest HeadlinesTweet-
Despite @CDCgov and @US_FDA approval of #COVID19 vaccination for children ≥5 years, many parents remain wary. @NEJM research suggests that #BNT162b2 poses no serious adverse effects and is 90.7% effective at preventing COVID-19 in 5- to 11-year-olds https://t.co/6DWfqKe523
-
-
Mashup Score: 3
In a prospective observational study, two doses of BNT162b2 were effective against confirmed and probable Beta infections. Through the end of June 2021, introductions of Beta did not interrupt control of the pandemic in Israel.
Source: EClinicalMedicineCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
A new study estimated #BNT162b2 #vaccine effectiveness against Beta infections in #Israel. Read more here: https://t.co/43kqqV1sYW https://t.co/jPU3IDA6eT
-
-
Mashup Score: 3
In a prospective observational study, two doses of BNT162b2 were effective against confirmed and probable Beta infections. Through the end of June 2021, introductions of Beta did not interrupt control of the pandemic in Israel.
Source: EClinicalMedicineCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
A news study estimated #BNT162b2 vaccine effectiveness against Beta infections in #Israel Read more: https://t.co/2uxW0I2K3O https://t.co/c4VONDmrhn
-
-
Mashup Score: 0Longitudinal SARS-CoV-2 mRNA vaccine-induced humoral immune responses in cancer patients - PubMed - 2 year(s) ago
Longitudinal studies of SARS-CoV-2 vaccine-induced immune responses in cancer patients are needed to optimize clinical care. In a prospective cohort study of 366 (291 vaccinated) patients, we measured antibody levels [anti-spike (IgG-(S-RBD)) and anti-nucleocapsid immunoglobulin] at three timepoints …
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet-
Our results from the longitudinal @NIH @theNCI #SeroNet #CORALE study on #antibody response from #mRNA-1273 and #BNT162b2 #COVID19 vaccines in pts w/cancer receiving #IO and #systemictherapy in @CR_AACR as part of a multi-institute collab https://t.co/R5BdTa19Qt @CedarsSinai https://t.co/UgMgGp4eQC
-
-
Mashup Score: 4Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia - 2 year(s) ago
Patients with chronic lymphocytic leukemia (CLL) have an increased risk for severe COVID-19 disease and mortality. The goal of this study was to deter…
Source: www.sciencedirect.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Efficacy of the #BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia Read it here in @Bloodjournal: https://t.co/KeLob0PyXF #clinicaltrialsandobservations @ASH_hematology #covid19 #leukemia #lymphocytic https://t.co/m1Lm4ssfrT
-
-
Mashup Score: 0Long-term immunogenicity of BNT162b2 vaccination in older people and younger health-care workers - 3 year(s) ago
The COVID-19 mRNA vaccine BNT162b2 (Comirnaty) is highly immunogenic and effective in preventing severe illness.1 Studies have indicated decreasing anti-SARS-CoV-2 antibody concentrations, but largely stable vaccine efficacy and effectiveness 6 months after vaccination.2,3 The emergence of variants of concern (VOCs), such as the delta (B.1.617.2) VOC, has raised concerns about waning protection,…
Source: The Lancet Respiratory MedicineCategories: Latest Headlines, PulmonologyTweet-
NEW Correspondence—Markers of immunity are reduced after regular 2-dose regimen of #BNT162b2 in older vs younger adults (39% of older pts lacked detectable serum neutralising activity against delta VOC at 6-m follow-up) From the EICOV/COVIM Study Group https://t.co/1W28WIF4Jb https://t.co/48d8xkui0n
-
"In this @JNCI_Now Editorial, Thakker et al appraise the study reporting safety & immunogenicity of the #BNT162b2 mRNA #COVID19 Vaccine Among Patients with Actively Treated #Cancer. Read more here: Original study: https://t.co/ymRBy3Wlsd Editorial: https://t.co/8NAvFEp805" https://t.co/pKzUzF25PG